← Back to Search

Alkylating agents, Anti-tumor antibiotic

Chemoradiotherapy for Esophageal Cancer (PaRCUS Trial)

Phase 2

Recruiting

Led By Marc Kerba, MD

Research Sponsored by AHS Cancer Control Alberta

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Biopsy proven carcinoma of the esophagus

Not a candidate for radical/curative treatment due to the advanced nature of the disease, presence of metastases, or intercurrent illness

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

PaRCUS Trial Summary

This trial seeks to show that adding carboplatin and paclitaxel chemo to radiation improves swallowing and quality of life for patients with inoperable esophageal cancer.

Who is the study for?

This trial is for adults with advanced esophageal cancer who can eat some solids, have a decent performance status, and proper organ function. They must start treatment within two weeks of consent, not be pregnant or breastfeeding, use effective contraception, and cannot have had previous chest radiation or chemotherapy for esophageal cancer.Check my eligibility

What is being tested?

The study tests if adding carboplatin and paclitaxel (chemotherapy drugs) to external beam radiation improves swallowing difficulties and life quality in patients with inoperable esophageal cancer compared to radiation alone.See study design

What are the potential side effects?

Possible side effects include nausea, vomiting, hair loss from chemotherapy; fatigue from both treatments; lowered blood counts leading to increased infection risk; kidney or liver stress shown by lab tests; and potential damage to nearby organs from radiation.

PaRCUS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My esophageal cancer has been confirmed by a biopsy.

Select...

My condition cannot be cured due to its advanced stage or other health issues.

Select...

I can only eat some solid foods due to my swallowing difficulty.

Select...

I am 18 years old or older.

Select...

I can take care of myself but might not be able to do heavy physical work.

PaRCUS Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of patients who achieve relief of dysphagia

Secondary outcome measures

Dysphagia progression free survival

PaRCUS Trial Design

1Treatment groups

Experimental Treatment

Group I: Chemotherapy with Concurrent RadiationExperimental Treatment2 Interventions

Carboplatin and paclitaxel will be administered intravenously on Days 1 and 8 while radiation therapy is administered

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

External Beam Radiation

2014

Completed Phase 2

~70

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

AHS Cancer Control AlbertaLead Sponsor

182 Previous Clinical Trials

36,162 Total Patients Enrolled

Marc Kerba, MDPrincipal Investigator403 521 3164

Media Library

Carboplatin and Taxol (paclitaxel) (Alkylating agents, Anti-tumor antibiotic) Clinical Trial Eligibility Overview. Trial Name: NCT02297217 — Phase 2

Esophageal Cancer Research Study Groups: Chemotherapy with Concurrent Radiation

Esophageal Cancer Clinical Trial 2023: Carboplatin and Taxol (paclitaxel) Highlights & Side Effects. Trial Name: NCT02297217 — Phase 2

Carboplatin and Taxol (paclitaxel) (Alkylating agents, Anti-tumor antibiotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02297217 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open enrolment opportunities for this clinical trial?

"Indeed, the information hosted on clinicaltrials.gov suggests that this medical trial is actively recruiting participants. First posted on November 21st 2019, it was last updated on March 23rd 2022 and is looking to enrol 50 patients from 1 centres."

Answered by AI

To what conditions have Carboplatin and Taxol (paclitaxel) been known to offer relief?

"Carboplatin and Taxol (paclitaxel) is commonly prescribed to treat melanoma. Moreover, this drug combination has been found effective in addressing neoplasm metastasis, lymphoma, non-Hodgkin's disease as well as advanced sarcoma."

Answered by AI

How many participants are taking part in this clinical experiment?

"Affirmative. The clinicaltrials.gov page for this medical trial indicates that it is currently recruiting participants, having been originally posted on November 21st 2019 and most recently edited on March 23rd 2022. This study needs 50 patients from 1 centre to be enrolled into the program."

Answered by AI

Has the Food and Drug Administration sanctioned Carboplatin and Taxol (paclitaxel) to be used therapeutically?

"While there is some evidence indicating the safety of Carboplatin and Taxol (paclitaxel), as this study is a Phase 2 trial, it was assigned a score of 2."

Answered by AI

Are there any published accounts of research focused on the combination of Carboplatin and Taxol (paclitaxel)?

"Presently, 1174 experiments with Carboplatin and paclitaxel are running concurrently. Of the 332 trials in Phase 3, Shanghai has a lion's share of these clinical studies; however, there are 66513 total active sites across the globe researching this treatment combination."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Chemoradiotherapy for Advanced Esophageal Cancer

Marc Kerba 2019. "Chemoradiotherapy for Advanced Esophageal Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02297217.

All > Esophagus Cancer > Esophageal Cancer